Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPRE-T: Aspirin versus placebo for preeclampsia prevention in twin pregnancies
2023-503698-40-00Phase 3Authorised
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in preeclampsia comparing Aspirin with Placebo (2 arms). Primary endpoint: Incidence of preeclampsia with delivery before 37 weeks' gestation. Planned start Mar 2023; status: authorised.
02
Drugs
aspirin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on 2023-503698-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503698-40-00.